Andros Pharmaceuticals Co., Ltd. (6917)

Overview

Andros Pharmaceuticals Co., Ltd is a pioneering force in the biopharmaceutical sector, focused on the innovation of novel drug delivery platform technologies. Since its establishment in 2008, the company has been at the forefront of developing cutting-edge solutions aimed at addressing complex medical conditions. Situated in Zhubei, Taiwan, Andros Pharmaceuticals dedicates itself to the research, development, and advancement of pharmaceuticals that promise to transform the therapeutic landscape. Through its vigorous pursuit of breakthroughs in drug delivery systems, Andros Pharmaceuticals is charting a course towards realizing the full potential of pharmacological interventions for a myriad of health issues.

Products and Services

The company’s product pipeline is distinguished by a range of innovative pharmaceutical solutions at various stages of clinical trials, each designed to offer significant advancements in the treatment of pain and other conditions:

• APC101: A fast-drying, film-forming, meter-dosed spray currently in Phase IIa clinical trials aimed at treating pain associated with post-herpetic neuralgia. This platform technology exemplifies Andros Pharmaceuticals' commitment to developing non-invasive, patient-friendly pain management solutions.
• APC201: In the Phase I/II clinical trial stage, APC201 represents a novel dosage form of topical anesthetic intended for the treatment of Osteoarthritis. This product underscores the company’s dedication to improving the quality of life for individuals suffering from chronic conditions.
• siRNA: A promising anti-sense oligonucleotide and DNA candidate, showcasing Andros Pharmaceuticals' exploration into genetic approaches for disease management. This venture into siRNA technology highlights the company’s investment in cutting-edge scientific research to pave new pathways for treatment.
• APC310 and APC501: Preclinical phase products designed for anesthesia related to intravenous catheter placement and venipuncture, respectively. These innovations are geared towards minimizing discomfort and improving patient experiences during common medical procedures.
• APC401: A special emulsified solution under development for the anesthesia of post-surgery pain, further illustrating the company’s efforts to address post-operative care and enhance recovery processes.
• LALP Cream: A topical cream for dermal analgesic applications, leveraging advanced formulation technology to deliver effective pain relief directly to the site of discomfort.
• iMinos Solution: Developed for the treatment of Alopecia Androgenetica, this solution reflects Andros Pharmaceuticals’ focus on addressing dermatological conditions with innovative approaches.
• T4 Endonuclease V: Part of the company’s diverse portfolio, aimed at tackling genetic markers associated with certain diseases. This product signifies Andros Pharmaceuticals' broader strategy of targeting the underlying causes of conditions at the molecular level.